Shire to acquire specialty drugmaker NPS Pharmaceuticals for $5.2 Billion

Shire now wants to pursue its goal to become a biotech powerhouse through acquisitions.

Shire now wants to pursue its goal to become a biotech powerhouse through acquisitions.

Irish drugmaker Shire PLC announced Sunday it has agreed to pay $5.2bn (£3.4bn, €4.4bn) in cash to acquire New Jersey-based NPS Pharmaceuticals Inc., which specializes in drugs for uncommon conditions.

Shire, best known for medications to fight hyperactivity, was founded in the UK, but is managed in Boston, headquartered in Dublin, and generates most of its sales in the US. The drugmaker now wants to pursue its goal to become a biotech powerhouse through acquisitions.

Under the terms of the deal authorized by the boards of directors from both corporations, Shire will acquire all the outstanding shares of NPS Pharma for $46-per-share in money, representing a 51% premium on its current price.

The deal is Shire’s first after AbbVie’s attempts to acquire Shire collapsed last October. Shire received a breakup fee of $1.6 billion after AbbVie walked away from the $55 billion deal. AbbVie abandoned the acquisition after the U.S. government created limitations to deter such tax-lowering deals.

The takeover will expand Shire’s portfolio of specialty drugs, drugs for niche diseases and conditions that normally command much larger price tags than conventional drugs. Shire’s greatest-selling drugs include the attention deficit disorder drugs Vyvanse and Adderall XR.

“Shire will accelerate the growth of NPS Pharma’s innovative portfolio through its market expertise in gastrointestinal (GI) disorders, core capabilities in rare disease patient management, and global footprint,” the company said in a statement.

Bedminster, New Jersey-based NPS is known for its two new drugs, Gattex an injection to treat a potentially deadly bowel disorder that lessens the body’s capacity to absorb nutrients and fluids and Natpara for hypoparathyroidism, is awaiting approval from the US Food and Drug Administration.

Gattex, which costs around $376,200 per year, had $67.9 million in sales during the first nine months of 2014. NPS earned total revenue of $157.4 million during the period.

“The acquisition of NPS Pharma is a significant step in advancing Shire’s strategy to become a leading biotechnology company,” said CEO Flemming Ornskov. “With our global strength and expertise in both rare diseases and GI, Shire is uniquely positioned to drive the continued success of GATTEX/REVESTIVE and if approved, commercialize NPS Pharma’s pipeline compound NATPARA/NATPAR.”

The acquisition deal is expected to be finished in the first quarter of 2015. It would be accretive to earnings in 2016, according to Ornskov. Shire hopes to pay the consideration with an $850m bank loan, cash reserves and an existing $2.1bn revolving credit facility.

Carrie Ann
Carrie Ann is Editor-in-Chief at Industry Leaders Magazine, based in Las Vegas. Carrie covers technology, trends, marketing, brands, productivity, and leadership. When she isn’t writing she prefers reading. She loves reading books and articles on business, economics, corporate law, luxury products, artificial intelligence, and latest technology. She’s keen on political discussions and shares an undying passion for gadgets. Follow Carrie Ann on Facebook

Leave a Reply

Your email address will not be published.

Recent Posts

Beeple Getting Hacked Resulted in His Followers Losing Over $438,000 in Crypto

Beeple Getting Hacked Resulted in His Followers Losing Over $438,000 in Crypto

Two tweets were posted using NFT artist Beeple’s account. The first one promoted an exclusive collection with Louis Vuitton. The second tweet announced that Beeple would soon rel
8 hours ago
Microsoft Selling Metaverse to Kawasaki: It’s A Whole New World

Microsoft Selling Metaverse to Kawasaki: It’s A Whole New World

Microsoft’s corporate vice president of mixed reality, Jessica Hawk, recently told CNBC that the metaverse will change how people function across a variety of devices and platfor
10 hours ago
Cryptocurrency Market Updates: Bitcoin Could Hit $500,000 Per Coin

Cryptocurrency Market Updates: Bitcoin Could Hit $500,000 Per Coin

On March 15, Novogratz went so far as to predict that the Bitcoin future price will reach half a million dollars per coin by 2027. He made this statement at the Bitcoin 2022 confer
1 day ago
Klarna CEO Uses Pre-Recorded Message For Laying Off Employees

Klarna CEO Uses Pre-Recorded Message For Laying Off Employees

Managers and HR personnel must be coached on how to compassionately convey the message as it is one of the most difficult conversations an individual can have. Open and honest comm
1 day ago
China Might No Longer Be An Apple Manufacturing Country

China Might No Longer Be An Apple Manufacturing Country

The iPad manufacturer has previously sought to remove China as the main Apple manufacturing country. Trade tensions and a strict Covid-19 policy has previously resulted in supply c
2 days ago
D.C. Refuses to Let Zuckerberg Wash His Hands Off Cambridge Analytica

D.C. Refuses to Let Zuckerberg Wash His Hands Off Cambridge Analytica

In the same year, Racine had sued Meta, then known as Facebook, for failing to protect user privacy and deceiving them about how much data is collected and how it was used. The Att
2 days ago